**List of Study Group 2015-2016
\*\*\*2015\*\*\***

1. Hatanaka M, Miyamura T, Koh K, Taga T, Tawa A, Hasegawa D, et al. Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group. Int J Hematol. 2015; 101:322-33.
\*\*\*2016\*\*\*
2. Rika S,· Masataka T, Kumi O, Takehiko M, Hiroatsu A, Souichi A, et al.·A comparison of tacrolimus and cyclosporine combined

with methotrexate for graft‑versus‑host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. Int J Hematol. 2016; 101:322-33.

1. Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa, H, et al. Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children’s Cancer Study Group. Int J Hematol. 2016; 103:416-22.
2. Masaki Y, Kawabata H, Takai K, Kojima M, Tsukamoto N, Ishigaki Y, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016; 103:686-92.
3. Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016; 104: 99-109.
4. Koh K, Ogawa C, Okamoto Y, Kudo K, Inagaki J, Morimoto T, et al. Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan. Int J Hematol. 2016; 104:245-55.

【2017】

1. Ishiguro A, Ezinne CC, Michihata N, Nakadate H, Manabe A, Taki M, et al. Pediatric thromboembolism: a national survey in Japan, 10.1007/s12185-016-2079-y
2. MiyamotoT, Takashima S, Kato K, Takase K, Yoshimoto G, Yoshida S, et al., Comparison of cyclosporine and tacrolimus combined with mycophenolate mofetil in prophylaxis for graft-versus-host disease after reduced-intensity umbilical cord blood transplantation, 10.1007/s12185-016-2093-0
3. Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, et al. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation, 10.1007/s12185-016-2120-1
4. Komatsu N, Kirito K. Shimoda K, Ishikawa T, Ohishi K, Ohyashiki K, et al. Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis, 10.1007/s12185-016-2130-z
5. Nakane T, Nakamae H, Yamaguchi T, Kurosawa S, Okamura A, Hidaka M, et al., Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials, accepted on 11/17/2017